Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
11:02am, Thursday, 09'th Nov 2023
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales
12:47pm, Thursday, 02'nd Nov 2023
Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.
Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript
02:36pm, Wednesday, 01'st Nov 2023
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - C
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
09:46am, Wednesday, 01'st Nov 2023
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.75 per share a year ago.
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
07:00am, Wednesday, 25'th Oct 2023
WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2
New Strong Buy Stocks for October 24th
08:16am, Tuesday, 24'th Oct 2023
MFA, GFF, OPI, APLS and GRPN have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2023.
Pharma Stock Upgraded on Eye Disorder Drug Sales
11:01am, Friday, 06'th Oct 2023
Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock is enjoying a boost today after an upgrade from J.P.
Trending stocks October 6, 2023: E.l.f. Beauty, Apellis Pharma, AutoZone:
10:41am, Friday, 06'th Oct 2023
Stocks take in the morning's September jobs report data. e.l.f. Beauty (ELF) shares tick up this morning following an upgrade to "Buy" from Jefferies analysts.
Why Shares of Apellis Pharmaceuticals Were Down Wednesday
03:10pm, Wednesday, 27'th Sep 2023
Apellis just got a J-code for reimbursement for its lead therapy from CMS. The company saw revenue climb 473% year over year in the second quarter.
Apellis Pharmaceuticals sees schadenfreude stock boost as rival trial fails
09:48am, Tuesday, 19'th Sep 2023
Apellis Pharmaceuticals Inc (NASDAQ:APLS) investors enjoyed some financial schadenfreude, with its stock rising over 9% in early deals after a rival Astellas Pharma Inc failed in a trial of an intende
Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts
08:38am, Tuesday, 19'th Sep 2023
Apellis Pharmaceuticals Inc. shares APLS, +5.76% jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc. ALPMY, , on Monday released results of a trial of Izervay as
Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?
12:46pm, Wednesday, 30'th Aug 2023
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis (APLS) Dips on Layoffs Amid Syfovre Safety Issues
09:46am, Wednesday, 30'th Aug 2023
Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
07:00am, Wednesday, 30'th Aug 2023
WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will par
Apellis Layoffs 2023: What to Know About the Latest APLS Job Cuts
09:24am, Tuesday, 29'th Aug 2023
Apellis Pharmaceuticals (NASDAQ: APLS ) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts. Apellis Pharmaceuticals has announced that it will b
